Recombinant Monoclonal Antibodies for BoNT/A Cleaved SNAP25 Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting botulinum neurotoxin type A (BoNT/A) within neurons are challenging due to its high potency and low concentration, leading to difficulties in precisely tracking its location and movement within cells, and existing antibodies often mislead results by recognizing both cleaved and intact SNAP25 proteins.
Innovation Solution
Development of highly specific recombinant monoclonal antibodies that preferentially bind to BoNT/A-cleaved SNAP25, allowing for precise detection in various tissue types and assays without recognizing full-length SNAP25, enabling accurate diagnosis of BoNT/A exposure and activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing antibodies are used to detect SNAP25, then detection can be performed, but the antibodies recognize both cleaved and intact SNAP25 proteins leading to misleading results
Solution Approach 1:
The antibody specifically targets the cleaved fragment of SNAP25 (residues 1-197) rather than the full-length protein, segmenting the detection target to distinguish cleaved from intact forms. This segmentation allows the antibody to bind only to the N-terminal fragment produced by BoNT/A cleavage, eliminating cross-reactivity with full-length SNAP25 and resolving the contradiction between detection capability and result reliability
Solution Approach 2:
A synthetic peptide corresponding to the N-terminal sequence of cleaved SNAP25 (residues 19-38) is used as an intermediary to immunize animals and generate the specific antibody. This peptide intermediary captures the essential epitope of the cleaved protein while being easier to produce and purify, enabling the development of highly specific antibodies that distinguish cleaved from intact SNAP25
2Measurement precision
If BoNT/A is detected directly using antibodies, then toxin location can be identified, but detection is difficult due to high potency and extremely low concentration within neurons
Solution Approach 1:
Instead of attempting to detect the harmful toxin directly at trace levels, the method converts the harmful enzymatic activity of BoNT/A into a beneficial detection signal. The toxin's cleavage of SNAP25 creates a stable, abundant N-terminal fragment that serves as a proxy marker. This fragment is present in much higher quantities than the original toxin, making detection feasible while the specific antibody ensures the signal reflects actual toxin activity rather than background noise
Solution Approach 2:
The method performs preliminary enzymatic cleavage of SNAP25 by BoNT/A before detection. Rather than detecting the toxin molecule itself, the approach allows the toxin to first perform its natural cleavage function, generating the detectable SNAP25(1-197) fragment. This preliminary action amplifies the signal and simplifies detection, as the cleaved fragment is more abundant and easier to detect than the original low-concentration toxin
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively detect BoNT/A-cleaved SNAP25 in tissue samples, providing a reliable method for diagnosing BoNT/A activity and efficacy, with minimal non-specific binding, thus overcoming the limitations of existing detection techniques.
Implementation Method 1
highly specific recombinant monoclonal antibodies that preferentially bind to BoNT/A-cleaved SNAP25
Data Source
Figure 1
Figure 2A~2F
Figure 3A~3F
AI summary
Methods and compositions for detecting BoNT/A enzymatic activity in tissues or a tissue sample are described herein. The invention encompasses antibodies that bind preferentially to BoNT/A cleaved SNAP25 and is able to preferentially detect BoNT/A cleaved SNAP25, as compared to intact (non-cleaved) SNAP25, in a tissue sample.